Figure 1
CKD-506 dose-dependently decreased the clinical scores, inflammatory cell infiltration, and demyelination in the experimental autoimmune encephalitis (EAE) mouse model under the prophylactic regimen. C57BL/6 mice were orally administered CKD-506 (3, 10, 30, or 100 mg/kg bodyweight) or fingolimod (0.1, 0.3, or 1 mg/kg bodyweight) daily from day 6 post-myelin oligodendrocyte glycoprotein35–55 immunization (a–e). The clinical score (a), maximum clinical score (n = 6–24 per group) (b), inflammatory cell infiltration [n = 6 per group for the fingolimod (1 mg/kg)-treated group; n = 8 per group for the fingolimod (0.1 mg/kg)-treated group; n = 9 per group for the fingolimod (0.3 mg/kg)-treated group; n = 17 per group for the non-immunized groups and CKD-506 (3 mg/kg)-treated group; n = 24 per group for the other groups] (c), and demyelination [n = 6 per group for the fingolimod (1 mg/kg)-treated group; n = 8 per group for the non-immunized groups, CKD-506 (3 or 10 mg/kg)-treated group, and fingolimod (0.1 or 0.3 mg/kg)-treated group; n = 9 per group for the other groups] (d) were examined. (e) Representative images of H&E-stained and Luxol fast blue-stained sections. Data are presented as mean ± SD; one-way ANOVA, followed by multiple comparisons post-hoc test with Tukey’s test for (b, d); Kruskal–Wallis test, followed by multiple comparisons post-hoc test with Dunnett’s test for (c). ###p < 0.001, non-immunized groups versus vehicle group; **p < 0.05 and ***p < 0.001, drug-treated group versus vehicle group; aaap < 0.001, CKD-506-treated group versus fingolimod (0.1 mg/kg)-treated group; bp < 0.05, bbbp < 0.001, CKD-506-treated group versus fingolimod (0.3 mg/kg)-treated group; ccp < 0.01, cccp < 0.001, CKD-506-treated group versus fingolimod (1 mg/kg)-treated group. N, non-immunized groups; V, vehicle group; Fin, fingolimod-treated group.
